Morgan Stanley
ALXO icon

Morgan Stanley’s ALX Oncology ALXO Stock Holding History

Morgan Stanley’s Portfolio ALXO Stock Details ALXO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$327K Buy
157,873
+59,038
+60% +$106K ﹤0.01% 5741
2026
Q1 		$198K Buy
98,835
+15,078
+18% +$28.7K ﹤0.01% 5878
2025
Q4 		$94.6K Sell
83,757
-1,533
-2% -$2.32K ﹤0.01% 6226
2025
Q3 		$156K Sell
85,290
-32,175
-27% -$27.9K ﹤0.01% 5981
2025
Q2 		$48.8K Sell
117,465
-240,995
-67% -$122K ﹤0.01% 6367
2025
Q1 		$223K Sell
358,460
-2,140,642
-86% -$2.57M ﹤0.01% 5687
2024
Q4 		$4.17M Buy
2,499,102
+2,178,330
+679% +$3.35M ﹤0.01% 4148
2024
Q3 		$584K Sell
320,772
-352,586
-52% -$1.31M ﹤0.01% 5329
2024
Q2 		$4.06M Buy
673,358
+330,221
+96% +$4.06M ﹤0.01% 4052
2024
Q1 		$3.83M Sell
343,137
-70,656
-17% -$992K ﹤0.01% 4128
2023
Q4 		$6.16M Buy
413,793
+80,310
+24% +$762K ﹤0.01% 3747
2023
Q3 		$1.6M Buy
333,483
+90,637
+37% +$492K ﹤0.01% 4523
2023
Q2 		$1.82M Sell
242,846
-71,340
-23% -$467K ﹤0.01% 4485
2023
Q1 		$1.42M Sell
314,186
-172,132
-35% -$1.3M ﹤0.01% 4654
2022
Q4 		$5.48M Buy
486,318
+89,681
+23% +$1.01M ﹤0.01% 3674
2022
Q3 		$3.8M Sell
396,637
-47,298
-11% -$551K ﹤0.01% 3921
2022
Q2 		$3.59M Buy
443,935
+59,417
+15% +$647K ﹤0.01% 4055
2022
Q1 		$6.5M Buy
384,518
+129,818
+51% +$2.22M ﹤0.01% 3394
2021
Q4 		$5.47M Buy
254,700
+173,280
+213% +$7.47M ﹤0.01% 3628
2021
Q3 		$6.01M Sell
81,420
-19,589
-19% -$1.31M ﹤0.01% 3477
2021
Q2 		$5.52M Buy
101,009
+96,452
+2,117% +$5.77M ﹤0.01% 3675
2021
Q1 		$336K Sell
4,557
-8,007
-64% -$630K ﹤0.01% 5371
2020
Q4 		$1.08M Buy
12,564
+10,665
+562% +$642K ﹤0.01% 4618
2020
Q3 		$72K Buy
+1,899
New +$74.6K ﹤0.01% 5567

Other funds holding ALXO

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
VP
venBio Partners San Francisco, California $519M AUM 339.42% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Morgan Stanley's ALXO Position: Q2 2026 in Review

Morgan Stanley increased its ALX Oncology (ALXO) stake by 60% in Q2 2026, buying an estimated $106K and bringing the position to 157,873 shares worth $327K. The position accounts for ﹤0.01% of the portfolio, ranked #5741.

Morgan Stanley first reported a position in ALXO in Q3 2020 and has held it in 24 quarters since. The position peaked at $6.5M in Q1 2022. 93 funds tracked by Wall St. Rank hold ALXO as of Q2 2026.

  • Morgan Stanley held 157,873 shares of ALX Oncology worth $327K as of Q2 2026.
  • Morgan Stanley bought 59,038 ALX Oncology shares in Q2 2026, an estimated $106K.
  • ALX Oncology made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #5741 holding.
  • Morgan Stanley first reported a position in ALX Oncology in Q3 2020 and has held it in 24 quarters since.
  • Morgan Stanley's ALX Oncology position peaked at $6.5M in Q1 2022.
  • 93 funds tracked by Wall St. Rank held ALX Oncology as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.